Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • TheraCann Australia and Ivory Medical have begun preparations for a new 54,000 sq. ft. purpose-built cultivation facility
  • Ivory Medical has commissioned this facility to provide industrial scale, EU GMP compliant, configurable white label medical cannabis products to foreign markets
  • The facility has been designed to produce up to 163 kilograms of dried cannabis flower (biomass) per year
  • TheraCann Australia has been contracted by Ivory Medical to provide technical and operational support for the facility
  • The cultivation technology selected is Sprout AI’s version 2 automated vertical indoor rolling rack enclosed plant habitat and root chamber technology 
  • Chris Bolton, Founder & CEO of TheraCann International sat down with Caroline Egan to discuss the cultivation facility
  • Sprout AI, a vertical farming technology company, opened trading at C$0.22 per share

TheraCann Australia and Ivory Medical have begun preparations for a new 54,000 sq. ft. purpose-built cultivation facility.

Ivory Medical has commissioned this facility to provide industrial scale, EU GMP compliant, configurable white label medical cannabis products to foreign markets. Under wholesale white label contracts, Ivory Medical will produce, process, and package medical cannabis products to meet client requirements.

This facility is comprised of a purpose-built 54,000 sq. ft. warehouse with a secure indoor vertical rack cultivation area measuring 43,000 sq. ft. The location will also house a secure indoor administration and processing area measuring 11,000 sq. ft. and has been designed to produce up to 163 kilograms of dried cannabis flower (biomass) per year. That biomass will then be extracted into oil to make cannabis oil-based products.

The cultivation technology selected is Sprout AI’s version 2 automated vertical indoor rolling rack enclosed plant habitat that can house up to 32 plants per habitat. The first partial order of 140 Sprout AI habitats is being prepared for shipment. Up to 1440 Sprout AI units will be utilized to produce Ivory Medical’s high-quality biomass for processing into medical-grade products.

TheraCann Australia has been contracted by Ivory Medical to provide technical and operational support for the facility. This five-year contract will include the receipt, installation, maintenance, and support of equipment to produce, process and prepare for the distribution of EU GMP compliant products.

Chris Bolton, Founder & CEO of TheraCann International sat down with Caroline Egan to discuss Ivory Medical’s fully configurable facility.

Sprout AI is a vertical farming technology company in the business of planning, designing, manufacturing and/or assembling sustainable and scalable AI-controlled vertical cultivation equipment for indoor vertical farming. 

Sprout AI (BYFM) opened trading at C$0.22 per share.

More From The Market Herald
Eve and Co - CEO, Melinda Rombouts

" Eve & Co (TSXV:EVE) releases 2021 year-to-date financial results

Eve & Co (EVE) reported gross revenues of $6.5 million in the first nine months of 2021.

" Elixxer Ltd. (TSXV:ELXR) welcomes new director

Elixxer (ELXR) is pleased to welcome Mr. Jeremy Green to the corporation’s board of directors. 
MediPharm Labs - CEO, Bryan Howcroft

" MediPharm Labs (TSX:LABS) announces medical cannabis delivery to Barbados

MediPharm Labs (LABS) has completed a medical cannabis export to Barbados in conjunction with partner Avicanna (TSX: AVCN).

" Mexican Supreme Court to vote on injunction allowing Xebra (CSE:XBRA) to commercialize cannabis

Xebra Brands (XBRA) has been informed that the Mexican Supreme Court will convene on Wednesday, December 1st.